Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders
暂无分享,去创建一个
Mauro Piacentini | Giuseppe Battaglia | Bart Devreese | Jozef Van Beeumen | F. Nicoletti | J. V. Van Beeumen | B. Devreese | F. Biagioni | G. Fimia | M. Piacentini | G. Battaglia | P. Mastroberardino | Ferdinando Nicoletti | Francesca Biagioni | M. G. Farrace | C. Busceti | Gemma Molinaro | G. Molinaro | G. Melino | Carla Letizia Busceti | Maria Grazia Farrace | Pier Giorgio Mastroberardino | Irene Viti | Gian Maria Fimia | Gennaro Melino | I. Viti
[1] G. Corsini,et al. Effects of Pretreatment with N‐(2‐Chloroethyl)‐N‐Ethyl‐2‐Bromobenzylamine (DSP‐4) on Methamphetamine Pharmacokinetics and Striatal Dopamine Losses , 1999, Journal of neurochemistry.
[2] S. Cardoso,et al. Mitochondrial function is differentially affected upon oxidative stress. , 1999, Free radical biology & medicine.
[3] Paul R. Sanberg,et al. 3-Nitropropionic acid animal model and Huntington' s disease , 1997, Neuroscience & Biobehavioral Reviews.
[4] S. Orrù,et al. Proteomics Identification of Acyl-acceptor and Acyl-donor Substrates for Transglutaminase in a Human Intestinal Epithelial Cell Line , 2003, Journal of Biological Chemistry.
[5] M. Piacentini,et al. Ornithine decarboxylase, transglutaminase, diamine oxidase and total diamines and polyamines in maternal liver and kidney throughout rat pregnancy. , 1986, The Biochemical journal.
[6] W. Voos,et al. Molecular chaperones as essential mediators of mitochondrial biogenesis. , 2002, Biochimica et biophysica acta.
[7] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[8] J. Blass,et al. Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria. , 2005, Biochemistry.
[9] J. V. Van Beeumen,et al. Mass spectrometric identification of mitochondrial oxidative phosphorylation subunits separated by two‐dimensional blue‐native polyacrylamide gel electrophoresis , 2002, Electrophoresis.
[10] M. Wieckowski,et al. Long‐chain fatty acids promote opening of the reconstituted mitochondrial permeability transition pore , 2000, FEBS letters.
[11] R. Graham,et al. Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. , 1994, Science.
[12] D. Turnbull,et al. Succinate-cytochrome c reductase: assessment of its value in the investigation of defects of the respiratory chain. , 1993, Biochimica et biophysica acta.
[13] C. Marsden,et al. Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.
[14] D. Sulzer,et al. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[15] G. Melino,et al. `Tissue' transglutaminase in cell death: a downstream or a multifunctional upstream effector? , 1998, FEBS letters.
[16] G. Johnson,et al. Impaired Mitochondrial Function Results in Increased Tissue Transglutaminase Activity In Situ , 2000, Journal of neurochemistry.
[17] P. Matarrese,et al. Tissue Transglutaminase Is a Multifunctional BH3-only Protein* , 2004, Journal of Biological Chemistry.
[18] O. H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.
[19] H. Schägger. Respiratory chain supercomplexes of mitochondria and bacteria. , 2002, Biochimica et biophysica acta.
[20] Robert M. Graham,et al. Transglutaminases: crosslinking enzymes with pleiotropic functions , 2003, Nature Reviews Molecular Cell Biology.
[21] M. Cookson,et al. Mitochondria and Dopamine New Insights into Recessive Parkinsonism , 2004, Neuron.
[22] G. Johnson,et al. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate‐independent mechanisms , 2005, Journal of neurochemistry.
[23] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[24] S. O'dell,et al. Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity , 1991, Brain Research.
[25] Joachim Klose,et al. Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice* , 2004, Journal of Biological Chemistry.
[26] H. Hefter,et al. Is levodopa toxic? , 2004, Journal of Neurology.
[27] Ikuko Miyazaki,et al. Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease , 2009, Neurotoxicity Research.
[28] G. Mardon,et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress , 2004, Development.
[29] R. Swerdlow,et al. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family , 1998, Annals of neurology.
[30] M. Beal,et al. Increased Vulnerability to 3‐Nitropropionic Acid in an Animal Model of Huntington's Disease , 1998, Journal of neurochemistry.
[31] G. Melino,et al. Gene Disruption of Tissue Transglutaminase , 2001, Molecular and Cellular Biology.
[32] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[33] H. Hashimoto,et al. Identification of amine acceptor protein substrates of transglutaminase in liver extracts: use of 5-(biotinamido) pentylamine as a probe. , 1998, Archives of biochemistry and biophysics.
[34] R. Swerdlow,et al. Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.
[35] J. Costentin,et al. Correlation between (3H)dopamine specific uptake and (3H)GBR 12783 specific binding during the maturation of rat striatum. , 1989, Life sciences.
[36] M. Beal. Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.
[37] Eric K. Richfield,et al. Risk factors for dopaminergic neuron loss in human α‐synuclein transgenic mice , 2004 .
[38] R. Ferrante,et al. Tissue Transglutaminase Is Increased in Huntington's Disease Brain , 1999, Journal of neurochemistry.
[39] D. D. Di Monte. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet. Neurology.
[40] F. Nicoletti,et al. Selective Blockade of mGlu5 Metabotropic Glutamate Receptors Is Protective against Methamphetamine Neurotoxicity , 2002, The Journal of Neuroscience.
[41] George Paxinos,et al. The Mouse Brain in Stereotaxic Coordinates , 2001 .
[42] M. Vila,et al. The rotenone model of Parkinson's disease , 2003, Trends in Neurosciences.
[43] G. Melino,et al. ‘Tissue’ transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease , 2002, Cell Death and Differentiation.
[44] L. Grivell,et al. Prohibitins act as a membrane‐bound chaperone for the stabilization of mitochondrial proteins , 2000, The EMBO journal.
[45] Donato A Di Monte,et al. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet Neurology.
[46] G. Melino,et al. Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[47] P. Jenner,et al. Understanding cell death in parkinson's disease , 1998, Annals of neurology.
[48] J. Trojanowski. Rotenone Neurotoxicity: A New Window on Environmental Causes of Parkinson's Disease and Related Brain Amyloidoses , 2003, Experimental Neurology.
[49] J. Greene,et al. Manipulation of Membrane Potential Modulates Malonate‐Induced Striatal Excitotoxicity In Vivo , 1996, Journal of neurochemistry.
[50] L. Seiden,et al. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine , 1980, Brain Research.
[51] G. Corsini,et al. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions. , 1997, The Journal of pharmacology and experimental therapeutics.
[52] B. Hyman,et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[53] G. Hofhaus,et al. Use of polarography to detect respiration defects in cell cultures. , 1996, Methods in enzymology.
[54] M. Beal,et al. Neurochemistry and toxin models in Huntington's disease. , 1994, Current opinion in neurology.
[55] C. Wollheim,et al. Mitochondrial function in normal and diabetic beta-cells. , 2001, Nature.
[56] Mauro Piacentini,et al. Transglutaminase 2: an enigmatic enzyme with diverse functions. , 2002, Trends in biochemical sciences.
[57] E. Hirsch,et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. , 2003, Human molecular genetics.
[58] F. Nicoletti,et al. Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors , 1999, Neuropharmacology.
[59] J. Schulz,et al. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra , 1997, Brain Research.
[60] Toru Itakura,et al. Metabolic inhibition enhances selective toxicity of l-DOPA toward mesencephalic dopamine neurons in vitro , 1997, Brain Research.
[61] J. C. Greene,et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[62] L. Grivell,et al. The Mitochondrial Prohibitin Complex Is Essential for Embryonic Viability and Germline Function in Caenorhabditis elegans* , 2003, Journal of Biological Chemistry.
[63] M. Hallett,et al. Levodopa in the treatment of Parkinson's disease: Current controversies , 2004, Movement disorders : official journal of the Movement Disorder Society.
[64] M. LaVoie,et al. Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine , 1999, The Journal of Neuroscience.
[65] J. Cooper,et al. Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.
[66] Todd B. Sherer,et al. Mechanism of Toxicity in Rotenone Models of Parkinson's Disease , 2003, The Journal of Neuroscience.
[67] B. Yamamoto,et al. The effects of methamphetamine on the production of free radicals and oxidative stress. , 1998, The Journal of pharmacology and experimental therapeutics.
[68] P. Matarrese,et al. Transglutaminase overexpression sensitizes neuronal cell lines to apoptosis by increasing mitochondrial membrane potential and cellular oxidative stress , 2002, Journal of neurochemistry.
[69] P. Jenner. Parkinson's disease, pesticides and mitochondrial dysfunction , 2001, Trends in Neurosciences.
[70] M. Beal,et al. Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.
[71] M. Murer,et al. Levodopa in Parkinson’s Disease , 1999, Drug safety.
[72] INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY , 1976 .
[73] Francesca Cicchetti,et al. Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease , 2005, Journal of the Neurological Sciences.